Compositions of a peptide targeting system for treating cancer
AssigneeNanoOncology, Inc.
InventorsThomas Primiano, Bey-Dih Chang, Jeremy Heidel
Life of this patent
Estimating the term…
Abstract
This invention describes a protein nanoparticle system for targeting siRNA or other drugs into tumors. The basis of the protein system is elastin-like peptides that self-assemble once exposed to the nucleic acid of the siRNA. Specific targeting peptides are fused to the core ELP structure by standard genetic engineering techniques. These targeting peptides confer specific binding of the nanoparticle to receptors on the surface of tumor cells and allow for uptake of the nanoparticle into the tumor cells.
Claims16
An isolated polypeptide capable of self-assembling with a siRNA molecule into a nanoparticle in solution, the isolated polypeptide comprising:
- a) an assembly domain (AD),
- b) a cell targeting domain (CTD) comprising the amino acid sequence of any one of SEQ ID NO:1-18 or SEQ ID NO:
- 20-27, the CDT being positioned at the N-terminal end of the isolated polypeptide;
- and
- c) a nucleic acid binding domain (NBD) capable of binding to an siRNA molecule, the NBD including a cationic domain, the NBD being positioned at the C-terminal end of the isolated polypeptide.
Dependencies are inferred from the claim text.